BAC has collaborated with Bristol-Myers Squibb to generate Captureselect affinity ligands, designed for purification and analysis of a proprietary type of targeted biologic called Adnectins.
Derived from human fibronectin, Adnectins are engineered using Bristol-Myers Squibb's proprietary Profusion technology to either block or stimulate the action of specific targets across a broad range of therapeutic areas.
The collaboration will focus on discovering and developing custom Captureselect ligands for the routine purification of Adnectin biologics.
According to BAC, the Captureselect platform enables the company to produce ligands that have high affinity and specificity for individual proteins.
These custom ligands are intended to simplify the purification process.
